Similarly, in astrocytoma, high levels of HO-1 have been associated with tumor grade II and III and poor overall survival [163], and NSCLC at stage III-IV, high levels of HO-1 have been associated with high mortality risk and short overall survival [118]. Here, HMOX1 is linked to astrocytoma (excluding glioblastoma).